Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-5495 in advanced malignancies
NCT06059508Phase 1Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-5495 in cancer, sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Dose limited toxicity up to 21 days, Adverse Events and Serious Adverse Events and 3 more. Started Oct 2023; status: recruiting.
02
Drugs
SHR-5495
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06059508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06059508.